UNTIRE: Cancer-related Fatigue With Digital Treatment
Primary Purpose
Colorectal Cancer, Fatigue
Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
UNTIRE App
Sponsored by
About this trial
This is an interventional supportive care trial for Colorectal Cancer focused on measuring Colorectal Cancer, Fatigue
Eligibility Criteria
Inclusion Criteria:
- >/= 18 years of age
- Owns a smart phone or Ipad
- Diagnosis of Recurrent Colorectal Cancer, adenocarcinoma
- Actively undergoing treatment for recurrent disease
- Speak and read English at a 6th grade level or higher
- A score of 1 or greater on the PRO CTACE DFCI fatigue (questions 53a or 53b)
Exclusion Criteria:
- Patients in Surveillance
- Patients receiving end of life care
- Patients taking dexamethasone other than for the control of nausea
- Patients taking methylphenidate (Ritalin) for the treatment of CRF
Sites / Locations
- Dana-Farber Cancer Institute
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
UNTIRE App
Arm Description
At baseline meeting participants will answer questionnaires and be introduced and instructed on self-managed use of Untire app treatment program. Participants will then have check in meetings assessing app usage and progress on weeks 4, 8 and 12 post baseline, then a final check-in 6 months post baseline.
Outcomes
Primary Outcome Measures
Enrollment Rate
Primary outcome is feasibility. Feasibility will be described as the number and percentage of enrolled patients that used the app more than once.
Secondary Outcome Measures
CSQ-I Score
Acceptability will be evaluated using the number and percentage of people that scored more than 16 points on the Client Satisfaction Questionnaire - Internet (CSQ- I).
Full Information
NCT ID
NCT05584540
First Posted
October 14, 2022
Last Updated
July 31, 2023
Sponsor
Dana-Farber Cancer Institute
1. Study Identification
Unique Protocol Identification Number
NCT05584540
Brief Title
UNTIRE: Cancer-related Fatigue With Digital Treatment
Official Title
The UNTIRE App Trial: The Feasibility of Using the Untire App for the Colorectal Cancer Patient to Manage Their Cancer Related Fatigue
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 30, 2023 (Anticipated)
Primary Completion Date
March 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Dana-Farber Cancer Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This research is being done to find out if using a smartphone app as digital treatment to reduce Cancer Related Fatigue is feasible and easy to use.
This research study is evaluating a smartphone application named the "Untire" app. The Untire app was designed as a digital treatment plan for people experiencing Cancer Related Fatigue (CRF).
Detailed Description
This is a single arm, pilot study evaluating the feasibility, acceptability, and effectiveness of a self-managed digital therapeutic application, the Untire App, for the treatment of cancer-related fatigue in the Colorectal (CRC) cancer patient community.
The Untire app was developed by Psychology Oncologists and combines proven treatments for Cancer Related Fatigue like cognitive behavioral therapy, mindfulness exercises, physical activities, education, and positive tips. The Untire app helps a patient recognize and learn about daily behaviors, fatigue levels, and energy levels. The Untire app has been tested on all different cancer types globally and has been proven to decrease fatigue and improve overall quality of life but this is the first-time investigators are examining the strengths and weaknesses of using the Untire app as a digital treatment plan for Cancer Related Fatigue.
The research study procedures include screening for eligibility and study interventions including smartphone app use and evaluations with questionnaires and follow up visits.
Participants will be in this research study for up to 12 months.
It is expected that about 60 people will take part in this research study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Fatigue
Keywords
Colorectal Cancer, Fatigue
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
UNTIRE App
Arm Type
Experimental
Arm Description
At baseline meeting participants will answer questionnaires and be introduced and instructed on self-managed use of Untire app treatment program.
Participants will then have check in meetings assessing app usage and progress on weeks 4, 8 and 12 post baseline, then a final check-in 6 months post baseline.
Intervention Type
Behavioral
Intervention Name(s)
UNTIRE App
Intervention Description
Digital therapeutic application
Primary Outcome Measure Information:
Title
Enrollment Rate
Description
Primary outcome is feasibility. Feasibility will be described as the number and percentage of enrolled patients that used the app more than once.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
CSQ-I Score
Description
Acceptability will be evaluated using the number and percentage of people that scored more than 16 points on the Client Satisfaction Questionnaire - Internet (CSQ- I).
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Ratings
Description
Patient's cancer related fatigue (CRF) will be described at baseline and at 4, 8, 12 weeks, and 6 months of treatment with the Untire app measured by The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) and its different subscale (e.g. physical, social, family, emotional, functional well-being, etc.)[13].
Time Frame
Baseline and at 4, 8, and 12 weeks.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
>/= 18 years of age
Owns a smart phone or Ipad
Diagnosis of Metastatic Colorectal Cancer, adenocarcinoma
Actively undergoing treatment for Metastatic disease
Speak and read English at a 6th grade level or higher
A score of 1 or greater on the PRO CTACE DFCI fatigue (questions 53a or 53b)
Exclusion Criteria:
Patients in Surveillance
Patients receiving end of life care
Patients taking dexamethasone other than for the control of nausea
Patients taking methylphenidate (Ritalin) for the treatment of CRF
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nina N Grenon, DNP, AOCN
Phone
(617) 632-5939
Email
ngrenon@partners.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nina N Grenon, DNP, AOCN
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nina N Grenon, DNP, AOCN
Phone
617-632-5939
Email
ngrenon@partners.org
First Name & Middle Initial & Last Name & Degree
Nina N Grenon
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD Sharing Time Frame
Data can be shared no earlier than 1 year following the date of publication
IPD Sharing Access Criteria
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Learn more about this trial
UNTIRE: Cancer-related Fatigue With Digital Treatment
We'll reach out to this number within 24 hrs